Thank you for subscribing!
Next Investors Jul 04, 2023
Last month, a big pharma company swooped on two treatments for a rare kidney disease in a US$3.5BN deal. This $3.5BN deal sets a benchmark price by big pharma on later stage assets treating rare kidney diseases. It also highlights the M&A appetite for kidney drug development.
Next Investors Jun 08, 2022
Yesterday our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), announced an agreement with the Australian Centre for Accelerating Diabetes Innovation to commence a clinical trial on Diabetic Kidney Disease expected Q4 2022.
Next Investors Apr 27, 2022
DXB is a long-term position for us, and despite its share price performance over recent weeks, we’re quietly satisfied with its progress to date - especially on the FSGS front.
Finfeed Feb 28, 2022
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.
Get expert stock analysis direct in your inbox
Next Investors Feb 28, 2022
Next Investors Feb 01, 2022
Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.
Finfeed Oct 21, 2021
Today DXB announced that the ethics approval was granted for its Phase III clinical trial on kidney disease FSGS, marking the “official start” of the trial.
Finfeed Aug 26, 2021
Yesterday Dimerix (ASX:DXB) announced its first “ethics submission” in Australia. Once approved, the patient recruitment process can begin for the Phase 3 trials. We will provide our commentary at every step in the process.
Finfeed Aug 16, 2021
Everything that you need to know about investing in Dimerix (ASX:DXB). A comprehensive summary of 9 reasons why we have invested in DXB. Upcoming projects, and milestones.
Join Our Mailing List
